(101 days)
The TGS Guidewire is indicated for any medical condition in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure in the field of ENT surgery, such as the paranasal sinuses, mastoid anatomy, can be identified relative to a CT- or MR- based model of the anatomy.
Example procedures include, but are not limited to:
- · Transsphenoidal access procedures
- Intranasal procedures
· Sinus procedures, such as maxillary antrostomies, sphenoidotomies/sphenoid explorations, turbinate resections, and frontal sinusotomies
- · ENT-related anterior skull base procedures
The TGS Guidewire is intended as an aid for precisely locating anatomical structures in either open or percutaneous procedures. It is intended for use with the Stryker ENT Navigation System and the XprESS LoProfile ENT Dilation System during balloon sinus dilation procedures.
The Scopis ENT Software is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
The Scopis ENT Software with TGS (Target Guided Surgery) is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
The TGS Guidewire is a single use, sterile, disposable instrument intended to be used with the Stryker ENT Navigation System and the XprESS LoProfile ENT Dilation System. The instrument is an electromagnetically navigated device which consists of a sensor in a protective sheath that can be inserted into the working lumen of the XprESS device, a bayonet connector to secure the device to the XprESS luer and a cable and plug to connect the device to the navigation system. The navigation system displays the position of the instrument in the preoperative scans.
The Scopis ENT Software is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
The Scopis ENT Software with TGS (Target Guided Surgery) is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
The provided text describes a 510(k) premarket notification for the TGS Guidewire and updated Scopis Software. It details the device, its intended use, and its substantial equivalence to predicate devices. However, the document does not contain information about an AI/ML component, a clinical study with a test set, ground truth establishmet, expert review, or MRMC studies. The document primarily focuses on demonstrating the substantial equivalence of the TGS Guidewire and updated Scopis Software to existing predicate devices through performance testing, rather than an AI/ML algorithm's performance against specific acceptance criteria in a robust clinical study.
Therefore, many of the requested elements for describing acceptance criteria and a study proving a device meets them are not applicable based on the provided text.
Here is a breakdown of the available and missing information based on your request:
1. A table of acceptance criteria and the reported device performance
The document mentions "Navigation accuracy" as a key performance metric for the TGS Guidewire. While it reports the device's performance, it does not explicitly state an acceptance criterion for this navigation accuracy. It implicitly uses the predicate device's performance as a benchmark for substantial equivalence.
| Performance Metric | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Navigation Accuracy | Not explicitly stated (implied to be comparable or better than predicate) | 0.75 ± 0.27mm |
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample Size for Test Set: Not applicable/Not mentioned. The performance data discussed is from "bench testing," not a clinical test set involving patient data.
- Data Provenance: Not applicable/Not mentioned for a clinical test set. The data is from internal bench testing.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable. The "ground truth" for navigation accuracy in bench testing would likely be based on precise measurement instruments, not expert human review.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. There is no mention of a test set requiring adjudication.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. There is no mention of a multi-reader multi-case study, nor an AI component where human readers would interact with AI. The device is a "Stereotaxic Instrument" and software for navigation, not an AI diagnostic tool.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
Not applicable. The device is a hardware guidewire used in conjunction with a navigation system and software, implying human interaction, not a standalone algorithm performing a task without human intervention. The "navigation accuracy" measured is for the combined system's ability to locate anatomical structures.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
For the navigation accuracy, the "ground truth" would be established by the precise measurement setup and instrumentation used in the bench testing. No clinical ground truth methods like expert consensus, pathology, or outcomes data are mentioned.
8. The sample size for the training set
Not applicable. There is no mention of a training set as this is not an AI/ML device that requires machine learning training data.
9. How the ground truth for the training set was established
Not applicable, as there is no training set mentioned.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image contains the logo for the U.S. Food and Drug Administration (FDA). The logo consists of two main elements: a seal on the left and the FDA acronym with the agency's name on the right. The seal features an abstract design with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around it. To the right of the seal, the acronym "FDA" is displayed in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
February 21, 2020
Stryker ENT Bruce Backlund Principal Regulatory Affairs Specialist 3600 Holly Lane North, Suite 40 Plymouth, Minnesota 55447
Re: K193118
Trade/Device Name: TGS Guidewire and updated Scopis Software Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic instrument Regulatory Class: Class II Product Code: PGW Dated: January 24, 2020 Received: January 24, 2020
Dear Bruce Backlund:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for Michael J. Ryan Director DHT1C: Division of ENT, Sleep Disordered Breathing, Respiratory and Anesthesia Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K193118
Device Name TGS Guidewire
Indications for Use (Describe)
The TGS Guidewire is indicated for any medical condition in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure in the field of ENT surgery, such as the paranasal sinuses, mastoid anatomy, can be identified relative to a CT- or MR- based model of the anatomy.
Example procedures include, but are not limited to:
- · Transsphenoidal access procedures
- Intranasal procedures
· Sinus procedures, such as maxillary antrostomies, sphenoidotomies/sphenoid explorations, turbinate resections, and frontal sinusotomies
- · ENT-related anterior skull base procedures
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(K) SUMMARY
| Date Prepared: | February 20, 2019 |
|---|---|
| Submitter Information: | Stryker ENT3600 Holly Lane North, Suite 40Plymouth, MN 55447 |
| Establishment Registration: | 3006345872 |
| Contact Information: | Bruce BacklundPrincipal Regulatory Affairs Specialist(763) 762-5902bruce.backlund@stryker.com |
| Device Information: | Trade Name: TGS GuidewireCommon Name: Stereotaxic InstrumentClassification: Class II, 21 CFR 882.4560Device: Ear, Nose, and Throat Stereotaxic InstrumentProduct Code: PGW |
Predicate Devices:
| Predicate Device | Manufacturer | 510(k) No. |
|---|---|---|
| Guidewire 0.6 Single Use | Fiagon GmbH | K161940 |
| Scopis Extended Instrument Set EM | Scopis GmbH | K171661 |
| Stryker ENT Navigation System EM | Scopis GmbH | K161491 |
Device Description:
The TGS Guidewire is a single use, sterile, disposable instrument intended to be used with the Stryker ENT Navigation System and the XprESS LoProfile ENT Dilation System. The instrument is an electromagnetically navigated device which consists of a sensor in a protective sheath that can be inserted into the working lumen of the XprESS device, a bayonet connector to secure the device to the XprESS luer and a cable and plug to connect the device to the navigation system. The navigation system displays the position of the instrument in the preoperative scans.
Image /page/3/Figure/7 description: This image shows a sensor connected to a plug via a bayonet connector. The sensor is a thin, cylindrical object that is connected to the bayonet connector by a thin wire. The bayonet connector is a square-shaped object that is used to connect the sensor to the plug. The plug is a rectangular object that is used to connect the sensor to an electrical outlet.
TGS Guidewire
{4}------------------------------------------------
| Name | Catalog Number | Surgical Planning Capability |
|---|---|---|
| Scopis ENT Software | 8000-020-001 | Without surgical planning capability |
| Scopis ENT Software with TGS | 8000-020-002 | With surgical planning capability |
The Scopis ENT software options include:
Intended Use:
The TGS Guidewire is intended as an aid for precisely locating anatomical structures in either open or percutaneous procedures. It is intended for use with the Stryker ENT Navigation System and the XprESS LoProfile ENT Dilation System during balloon sinus dilation procedures.
The Scopis ENT Software is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
The Scopis ENT Software with TGS (Target Guided Surgery) is an accessory to the Electromagnetic Navigation Unit and intended for controlling of the hardware of the navigation unit.
Indications for Use:
The TGS Guidewire is indicated for any medical condition in which the use of stereotactic surgery may be appropriate, and where reference to a rigid anatomical structure in the field of ENT surgery, such as the paranasal sinuses, mastoid anatomy, can be identified relative to a CTor MR- based model of the anatomy.
Example procedures include, but are not limited to:
- Transsphenoidal access procedures •
- Intranasal procedures .
- . Sinus procedures, such as maxillary antrostomies, ethmoidectomies, sphenoidotomies/sphenoid explorations, turbinate resections, and frontal sinusotomies
- ENT-related anterior skull base procedures .
Contraindications:
The instrument must not be exposed to MRI or used in a Magnetic Resonance Environment. The MRI exposure might magnetize the sensor.
Technological Characteristics and Substantial Equivalence:
The TGS Guidewire (subject device) has the same indications for use and fundamental scientific technology as the predicate device Guidewire 0.6 Single Use [K161940].
The subject device TGS Guidewire has the same technological characteristics (i.e., principal of operation, basic design, functionality, materials, biocompatibility, packaging, and sterilization) as the predicate device Guidewire 0.6 Single Use [K161940]. The subject guidewire and predicate guidewire are both single-use, sterile, pre-calibrated flexible guidewires with a sensor at the instrument tip, and both are compatible with the Stryker XprESS LoProfile device.
The Scopis ENT Software and Scopis ENT Software with TGS (subject device) has the same indications for use and fundamental scientific technology as the predicate devices Scopis Extended Instrument Set EM [K171661] and Scopis Hybrid Navigation System EM [K161491].
The subject Scopis ENT Software and Scopis ENT Software with TGS has the same technological characteristics (i.e., algorithm, architecture, planning functionalities, patient
{5}------------------------------------------------
registration, tracking method, position accuracy, and cyber security) as the predicate devices Scopis Extended Instrument Set EM [K171661] and Scopis Hybrid Navigation System EM [K161491]. The only difference is that the subject software user interface was updated to add a new icon to indicate the TGS Guidewire is the active instrument.
The TGS Guidewire and updated Scopis ENT Software have the same indications for use and fundamental scientific technology as the predicate devices [K161940, K171661, K161491]. The TGS Guidewire and updated Scopis ENT Software is substantially equivalent to the predicate devices.
Performance Data:
Performance testing for the TGS Guidewire included biocompatibility, design verification (dimensional, functional, strength, HFE/UE verification testing), packaging, shelf life and design validation (HFE/UE). Performance testing showed that the device meets design specifications and performs as intended.
Navigation accuracy was performed through bench testing in order to establish the substantial equivalence to the predicate devices. Testing was also completed to ensure functionality and compatibility with the ENT Navigation System.
The measured navigation accuracy using the TGS Guidewire is 0.75 ± 0.27mm compared to the Fiagon predicate device K161940 with a bench accuracy 1.27 ± 0.4mm.
Conclusion:
In conclusion, the TGS Guidewire and updated Scopis ENT Software indications for use and technological characteristics are the same as or equivalent to those of one or more of the predicate devices. The differences between the subject device and the predicate devices (e.g., update of user interface to add a new icon indicating the TGS Guidewire being the active instrument) do not raise different questions of safety or effectiveness and performance testing has been conducted to demonstrate the subject device performance is substantially equivalent to the predicate devices.
§ 882.4560 Stereotaxic instrument.
(a)
Identification. A stereotaxic instrument is a device consisting of a rigid frame with a calibrated guide mechanism for precisely positioning probes or other devices within a patient's brain, spinal cord, or other part of the nervous system.(b)
Classification. Class II (performance standards).